Six indirubin derivatives have been synthesized and their inhibitory effects on the growth of HL-60 human promyelocytic leukemia cells investigated. Cell viability was determined using the trypan blue exclusion method. Indirubin-3′-oxime (I-1) inhibited the growth of HL-60 cells with a GI 50 value of 36.6 µM, whereas I-0, I-2, I-3, I-4 and I-6 showed only weak cytotoxic activities against HL-60 cancer cells with GI 50 values in the range of 97.3 to over 100 μM. These results indicate that indirubin derivatives might be useful candidate agents for exploring potential antileukemic drugs.
Leukemia is a cancer of the blood or bone marrow characterized by an abnormal proliferation of blood cells, usually white. Like all cancers, human leukemia results from multiple mutations that lead to abnormalities in either the expression or function of gene products that affect the delicate balance between proliferation, differentiation and apoptosis [1] . According to its form and kinds of cells affected, leukemia is divided into four major kinds, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML) [2] . Up to date, there is no single known cause for all of the different types of leukemias and each is likely to have different causes. Known causes include natural or artificial ionizing radiation, viruses, such as human Tlymphotropic virus, and some chemicals, notably benzene and alkylating chemotherapy agents used for previous malignancies [3] . In 2009, the US National Institute of Health estimated that there were 44,790 new cases of leukemia and about 21,870 patients died from the disease in the United States [4] . Considerable amounts of research into the causes, diagnosis, treatment and prognosis of leukemia, and clinical trials are either being planned or being conducted in the world. Studies are focused on effective means of treatment, better ways of treating the disease, improving the quality of life for patients, and appropriate care in remission and after cures.
Indirubin was identified as an active ingredient of a Chinese traditional recipe called Danggui Longhui Wan, which is used in the treatment of a variety of diseases, including chronic myelocytic leukemia [5] . Recently, indirubin and its derivatives were found to be selective inhibitors of the cyclin-dependent kinases (CDKs) [6, 7] . Furthermore, indirubins were also reported as strong inhibitors of glycogen synthase kinase-3b (GSK-3b) [8] , c-Jun N-terminal kinase (JNK) [9] , Src kinase [10] , fibroblast growth factor receptor 1 (FGFR1) [11] , and the aryl hydrocarbon receptor [12] . Indirubin compounds were shown to inhibit the proliferation of a variety of cultured cell types by inducing arrest at G1/S or G2/M phase of the cell cycle [6] . They may contribute significantly to the treatment of various neurodegenerative diseases, such as Alzheimer's, Parkinson's, Nieman-Pick's, diabetes and cancer. Many new indirubin derivatives are thus synthesized and investigated for their pharmacological properties as a new promising family of anticancer and neuroprotective agents. In this publication we report results on the inhibitory effects of six indirubin derivatives on the growth of HL-60 human promyelocytic leukemia cells.
The synthesis of two new indirubin-3′-oxime derivatives (Scheme 1) was carried out by a substitution reaction between indirubin-3′-oxime and different halogen derivatives in N,N′-dimethylformamide (DMF).
We studied the inhibitory effects of six indirubin derivatives on the growth of HL-60 cells. In this, we used a trypan blue exclusion method instead of the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay to measure cell viability, because the indirubins are dark purple and similar to the purple formazan formed in the MTT assay. When HL-60 cells (3×10 5 cells/mL) were treated with 1, 10, 30 and 100 μM of the six indirubin derivatives for 3 days, we found that I-1 inhibited proliferation of HL-60 cells by 16.9%, 22.5%, 58.4%, and 100%, respectively ( Fig. 1 ). Thus, the IC 50 value for I-1 was about 36.6 µM. The other indirubin derivatives, I -0, I-2, I-3, I-4 and I-6, showed only weak cytotoxic activities on HL-60 cancer cells with GI 50 values in the range of 97.3 to over 100 μM.
Suzuki et al. have discovered that indirubin promoted neutrophilic differentiation of human myelocytic leukemia HL-60 cells probably through inhibition of CDK2 and activation of PU.1 [13] . Kim et al. reported the synthesis of indirubin derivatives and the enhancing effects of these on the differentiation induction of HL-60 cells by adding 1,25 dihydroxyvitamin-D3 and all-trans-retinoic acid [14] . It has been shown that indirubin-3′-oxime inhibits the growth of normal human lymphocytes and may be a potent immunosuppressive agent [15] .
In further study, we need to examine whether the growth-inhibitory effects of indirubin derivatives could arise from the induction of differentiation and/or apoptosis of HL-60 cells.
Experimental
General: NMR spectra were recorded by an AVANCE 500 MHz (Bruker-Germany) instrument, ESI-MS were measured on an Agilent 1100 Series LC/MSD Trap SL (Institute of Chemistry, Vietnam Academy of Science and Technology). Indirubin was isolated from Strobilanthes cusia leaves [16] .
Synthesis of indirubin-3′-oxime:
Indirubin (I-0, 262 mg, 1 mmol) was dissolved in 15 mL pyridine in a 100 mL round bottom flash. Then, hydroxylamine hydrochloride (181 mg, 2.6 mmol) was added and the solution was refluxed at 120 o C for 2 h. The reaction mixture was then cooled to room temperature and pyridine was removed under low pressure. The solid residue was washed several times with 1 N hydrochloric acid (100 mL) to completely remove pyridine. Having washed with distilled water to pH = 7, the crude product was air dried. The product was purified by redissolving in 1N sodium hydroxide (50 mL), filtered, and reprecipitated in 1N hydrochloric acid to yield I-1 as a red solid (263.5 mg, 93%).
Indirubin-3′-oxime (I-1)
Yield 93% of a red powder. 1 
Synthesis of O-derivatives of indirubin-3′-oxime:
A mixture of indirubin-3′-oxime (83 mg, 0.3 mmol), anhydrous dimethylformamide (DMF, 6 mL), appropriate halogen derivative (0.9 mmol) and triethyl amine as catalyst (120 μl, 0.9 mmol) was stirred at room temperature for 48 h. When reaction terminated, the solvent was removed under low pressure. Residues were washed several times with distilled water and dried to yield a crude product.
Indirubin-3′-[O-(3-bromoprop-1-yl)oxime] (I-2)
Yield 90% of a dark red powder. 
Indirubin-3′-[O-(methoxycarbonylmethyl)-oxime] (I-3)
Yield 87% of a red powder. 1 
Synthesis of acetylated derivatives:
The acetylated indirubin derivatives employed in these experiments were synthesized and characterized via two dimensional NMR spectroscopy in order to confirm their identity and purity [17] . In brief, a mixture of 10 mL acetic anhydride and 1 mmol indirubin or indirubin-3′-oxime were placed in a 50 mL round-bottomed flask. The reaction mixture was stirred well with a magnetic stirrer and refluxed for 5 h in an oil bath. Then, the solvent was removed under low pressure. Residues were washed several times with distilled water and dried to obtain crude products. Pure products were obtained by column chromatography with dichloromethane as eluent.
N-1-Acetylindirubin (I-4)
Yield 85% of a red powder. 1 
Cell viability (Trypan blue exclusion):
For studying cell viability, the trypan blue exclusion assay was performed [18] . Human leukemia HL-60 cell line was obtained from Korea Cell Line Bank (KCLB: Seoul, Korea) and cultured in RPMI-1640 medium (Gibco BRL, Grand Island, NY), supplemented with 10% FBS (Gibco BRL, Grand Island, NY), and 100 μg/mL streptomycin sulfate at 37°C in a 5% CO 2 atmosphere. In brief, HL-60 cells (3 × 105 cells /mL) were cultured in a 24-well plate. The cells were then treated with 1, 10, 30 and 100 μM of 6 indirubin derivatives. After 3 days, 100 µL of a suitable cell suspension was mixed with 100 µL 0.4% trypan blue solution and incubated for 2 min at 37ºC. The viable cells, trypan blueexcluded cells, were counted with a Neubauer hemocytometer under an inverted microscope. The viabilities of the indirubin derivative-treated cells were compared with the viability of untreated control. Results are presented as mean values from 3 replicate experiments.
